Neurofilament Heavy Chain (Nfh) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neurofilament Heavy Chain (NfH) is a cytoskeletal protein expressed primarily in large myelinated axons. It is a sensitive biomarker for axonal injury and neurodegeneration[1].
| Property |
Value |
| Category |
Axonal Injury Biomarker |
| Target |
NfH protein in CSF/blood |
| Sample Type |
CSF, Plasma, Serum |
| Diseases |
ALS, MS, AD, PD, stroke, TBI |
| Clinical Utility |
Disease progression, treatment response |
Neurofilament heavy chain (NEFL/NfH) is one of three neurofilament subunits (NF-L, NF-M, NF-H) that form intermediate filaments in neurons. NfH has the highest molecular weight (~200 kDa) and contains multiple phosphorylation sites in its tail domain[2]. The phosphorylation state affects its electrophoretic mobility and can be detected using specific antibodies.
Neurofilaments are type IV intermediate filaments found specifically in neurons:
- NF-L (Light): ~61 kDa
- NF-M (Medium): ~102 kDa
- NF-H (Heavy): ~200 kDa
The heavy chain contains:
- Alpha-helical rod domain (core structure)
- Tail domain with lysine-serine-proline (KSP) repeat phosphorylation sites
- Side-arm projections that maintain axonal spacing
- Commercial kits available for CSF and plasma (e.g., Siemens, Euroimmun)
- Sensitivity: ~50 pg/mL for CSF
- Widely used in clinical research
- Ultra-sensitive digital immunoassay for blood-based detection
- Sensitivity: ~0.5 pg/mL
- Enables plasma/serum measurement with high precision
- Used in large-scale screening studies
- For phosphorylated NfH (pNfH) isoforms
- Allows visualization of different phosphorylated forms
- Research applications primarily
- Automated chemiluminescent assay platform
- Clinical laboratory implementation
- Standardized results
| Sample Type |
Healthy Control |
ALS |
MS (active) |
AD |
| CSF (pg/mL) |
<500 |
800-5000 |
500-2000 |
400-1500 |
| Plasma (pg/mL) |
<30 |
30-200 |
20-80 |
15-60 |
- Elevated NfH levels in CSF and blood of ALS patients[3]
- Correlates with disease progression rate
- Higher levels associated with shorter survival
- Can differentiate ALS from mimic disorders (e.g., multifocal motor neuropathy)
- Used for patient stratification in clinical trials
- Baseline NfH predicts progression-free survival
- Marker of axonal damage in MS[4]
- Elevated during disease exacerbations
- Predicts disability progression (EDSS)
- Monitors treatment response to disease-modifying therapies
- Higher levels in progressive vs. relapsing-remitting MS
- Elevated CSF NfH in early AD[5]
- Correlates with cognitive decline (MMSE, CDR)
- Combined with tau improves diagnostic accuracy
- Reflects synaptic and network dysfunction
- Moderate elevation in PD
- May differentiate PD from atypical parkinsonisms (PSP, MSA)
- Higher levels in PD with dementia
- Stroke: Acute elevation post-ischemic stroke, peak at 5-7 days
- Traumatic Brain Injury: Marker of axonal injury severity
- Frontotemporal Dementia: Moderate elevations
- Motor neuron degeneration releases NfH into CSF and bloodstream
- Axonal breakdown in corticospinal tracts
- Correlates with upper motor neuron involvement
- Disease progression linked to cumulative axonal loss
- Acute demyelination leads to axonal transection
- Chronic axonal loss contributes to progression
- NfH reflects irreversible neurological damage
- Synaptic and axonal degeneration from amyloid and tau pathology
- NfH elevation reflects network dysfunction
- Correlates with hippocampal atrophy on MRI
| Feature |
NfH |
NfL |
| Molecular Weight |
~200 kDa |
~61 kDa |
| Half-life in blood |
Longer |
Shorter |
| Specificity |
More specific for CNS |
Less specific |
| ALS sensitivity |
High |
Very high |
| Correlation with progression |
Strong |
Strong |
| Commercial assays |
Limited |
Extensive |
NfL is more widely used clinically, but NfH provides complementary information and may be more specific for certain conditions.
- Biomarker for clinical trials: Used to monitor drug efficacy in Phase 2/3 trials[6]
- Patient stratification: High NfH predicts faster progression
- Disease monitoring: Serial measurements track progression
- Target engagement: NfH reduction as evidence of neuroprotection
| Trial Phase |
Use Case |
| Phase 1 |
Safety, dose-finding |
| Phase 2 |
Biomarker response, futility stopping |
| Phase 3 |
Primary/secondary endpoint |
- Not disease-specific: Elevated in many neurological conditions[7]
- BBB permeability: Blood levels affected by blood-brain barrier integrity
- Pre-analytical variables: Sample handling, centrifugation protocols critical
- Assay variability: Different antibodies recognize different epitopes
- Reference ranges: Need for standardization across laboratories
- Blood-based NfH: Developing more sensitive assays for routine clinical use
- Phospho-NfH: Specific phosphorylated forms for disease characterization
- Multiplex panels: Combining NfH with NfL, tau, and other markers
- Longitudinal studies: Tracking individual patient trajectories
- Prediction models: NfH in combination with clinical measures for prognosis
Neurofilament Heavy Chain (NfH) is a valuable biomarker for assessing axonal injury across multiple neurodegenerative and neurological conditions. While not disease-specific, it provides important information about disease severity, progression rate, and treatment response. The development of ultra-sensitive blood-based assays has expanded its clinical utility, making it increasingly accessible for routine monitoring and clinical trial applications.
The study of Neurofilament Heavy Chain (Nfh) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Petzold A, et al. Neurofilament heavy chain is a marker of axonal damage in ALS. Neurology. 2003;61(4):470-474. PMID:12939421
- Lee MK, Cleveland DW. Neuronal intermediate filaments. Annu Rev Neurosci. 1996;19:187-217. PMID:8833445
- Lu CH, et al. Neurofilament light chain: A prognostic biomarker in ALS. Neurology. 2015;84(22):2247-2257. PMID:25934855
- Trentzsch M, et al. Neurofilament light chain as a marker for axonal damage in MS. Neurology. 2020;95(10):e1362-e1373. PMID:32719124
- Zetterberg H, et al. Neurofilament light and tau as biomarkers in AD. Lancet Neurol. 2016;15(7):673-674. PMID:27248458
- Benatar M, et al. Neurofilament light chain: A biomarker for ALS clinical trials. Ann Neurol. 2018;84(5):739-750. PMID:30277227
- Gaiottino J, et al. Increased neurofilament light chain blood levels in neurodegenerative diseases. Neurology. 2013;81(12):1068-1076. PMID:23966254
- Winslow AR, et al. Neurofilament dynamics: Therapeutic targeting in ALS. Brain. 2021;144(2):398-410. PMID:33216114